adolfo
ignacio
mena
one
main
public
health
concern
emerg
virus
potenti
introduct
sustain
circul
among
popul
immunolog
suscept
host
induct
protect
immun
vaccin
power
tool
prevent
concern
confer
protect
popul
risk
convent
approach
develop
vaccin
emerg
pathogen
signific
limit
lack
experiment
tool
sever
emerg
virus
concern
poor
immunogen
safeti
issu
lack
crossprotect
antigen
variant
unpredict
emerg
futur
viru
threat
demand
capabl
rapidli
develop
safe
effect
vaccinesw
describ
recent
advanc
new
vaccin
strategi
explor
altern
classic
attenu
inactiv
vaccin
provid
exampl
potenti
novel
vaccin
emerg
virus
approach
might
appli
control
mani
emerg
pathogen
emerg
diseas
affect
livestock
human
repres
import
threat
world
economi
public
health
sever
factor
includ
increas
urban
intern
travel
commerc
climat
chang
increas
likelihood
threat
emerg
pathogen
continu
worsen
futur
viru
emerg
infectionfre
area
jump
new
speci
suscept
host
popul
like
littl
preexist
immun
pathogen
lack
herd
immun
result
fast
dissemin
virul
consequ
infect
provid
protect
immun
vaccin
power
costeffect
strategi
prevent
control
emerg
infecti
diseas
develop
vaccin
emerg
viru
might
face
sever
challeng
summar
box
although
convent
vaccin
strategi
base
inactiv
viru
use
life
attenu
strain
instrument
control
even
erad
import
anim
human
infecti
diseas
mani
case
fail
deliv
requir
level
immunogen
safeti
crossprotect
across
pathogen
antigen
variabl
even
exacerb
diseas
therefor
new
strategi
explor
obtain
safer
effect
vaccin
tabl
vaccin
base
immunolog
relev
viral
antigen
rather
whole
viru
could
satisfi
mani
challeng
summar
box
howev
individu
antigen
without
context
viral
infect
poorli
immunogen
therefor
expressiondeliveri
method
well
adjuv
review
must
care
design
reach
protect
articl
discuss
recent
advanc
use
novel
vaccin
strategi
control
emerg
virus
simplic
focu
relev
exampl
vaccin
approach
vaccin
platform
might
appli
develop
safer
effect
vaccin
number
emerg
virus
safe
strategi
induc
immun
respons
deliv
viral
antigen
produc
recombin
method
chemic
synthesi
addit
safeti
recombin
protein
vaccin
addit
advantag
first
product
requir
manipul
pathogen
avoid
risk
accident
escap
hurdl
high
biosafeti
biocontain
requir
second
vaccin
candid
design
even
limit
inform
pathogen
third
also
subunit
vaccin
use
overcom
natur
immunodomin
highli
variabl
epitop
direct
immun
respons
conserv
broadli
protect
epitop
fourth
sinc
individu
antigen
elicit
respons
differ
respons
induc
natur
infect
vaccin
strategi
could
use
diva
differenti
infect
vaccin
anim
vaccin
accompani
serolog
test
main
disadvantag
subunit
vaccin
isol
protein
peptid
usual
poor
immunogen
fail
recogn
pathogenassoci
molecular
pattern
pamp
activ
innat
immun
respons
requir
full
develop
acquir
immun
increas
respons
conserv
epitop
must
present
immunogen
conform
andor
accompani
potent
adjuv
recent
vaccin
candid
base
envelop
glycoprotein
pathogen
hendra
viru
hev
famili
paramyxovirida
genu
henipaviru
shown
induc
complet
protect
ferret
model
recombin
protein
immun
also
use
induc
broadli
reactiv
antibodi
influenza
viru
iav
conserv
epitop
vaccin
provid
longliv
protect
across
sever
iav
subtyp
also
known
univers
influenza
vaccin
would
avoid
need
annual
vaccin
continu
reformul
vaccin
match
circul
strain
would
protect
anim
iav
futur
pandem
strain
recombin
protein
vaccin
contain
highli
conserv
extracellular
domain
iav
protein
demonstr
safeti
immunogen
phase
clinic
trial
increas
immunogen
sequenc
express
four
tandem
copi
fuse
flagellin
ligand
act
adjuv
wang
colleagu
novel
vaccin
strategi
emerg
virus
mena
tabl
novel
strategi
appli
develop
vaccin
emerg
virus
advantag
disadvantag
exampl
safe
viral
replic
direct
respons
conserv
epitop
poor
immunogen
might
requir
use
potent
adjuv
boost
hev
glycoprotein
iav
iav
longahelix
viruslik
particl
nanoparticl
multimer
peptid
multimer
present
antigen
nativ
conform
safe
viral
replic
product
yield
cost
purif
limit
iav
headless
ha
particl
chikv
vlp
elicit
humor
cell
respons
high
level
antigen
express
sever
vector
platform
differ
profil
avail
preexist
immun
vector
decreas
efficaci
ndv
express
rvfv
glycoprotein
vsv
express
ebov
glycoprotein
yfv
attenu
strain
express
denv
glycoprotein
adjuv
effect
vector
low
cost
mass
product
limit
experiment
inform
clinic
trial
l
lacti
express
sarscoronaviru
n
protein
nucleic
acid
vaccin
safe
viral
replic
elicit
humor
cell
respons
replicon
increas
immunogen
poor
immunogen
enhanc
adjuv
heterolog
primeboost
strategi
dna
vaccin
wnv
hors
use
synthet
peptid
conserv
stalk
region
iav
hemagglutinin
ha
protein
figur
coupl
carrier
protein
keyhol
limpet
hemocyanin
klh
vaccin
two
dose
peptid
induc
crossreact
antibodi
protect
mice
lethal
challeng
differ
subtyp
iav
approach
includ
fusion
antigen
dendrit
cell
targetingactiv
molecul
strategi
result
deliveri
antigen
antigen
present
cell
appropri
stimulatori
context
investig
requir
understand
best
target
sequenc
result
high
immunogen
lack
reactogen
virion
structur
protein
usual
arrang
tight
wellord
conform
believ
recogn
pamp
therefor
one
way
increas
immunogen
viral
antigen
deliv
multimer
conform
viruslik
particl
vlp
review
vlp
base
envelop
nonenvelop
virus
use
immun
homolog
viru
engin
incorpor
epitop
differ
pathogen
addit
better
immunogen
vlp
consid
safe
contain
genet
materi
vlp
prepar
requir
use
inactiv
agent
ie
formalin
might
destroy
immunolog
relev
conform
epitop
vlp
approach
appli
research
toward
univers
iav
vaccin
review
steel
et
al
prepar
headless
ha
vlp
coexpress
delet
ha
protein
lack
highli
variabl
head
domain
figur
along
hiv
gag
protein
mice
immun
headless
ha
vlp
induc
broadli
reactiv
antibodi
conserv
stalk
region
ha
protect
challeng
lethal
dose
homolog
viru
influenza
viru
antigen
conjug
hepat
viru
core
protein
self
assembl
vlp
acamflua
demonstr
safeti
immunogen
phase
clinic
trial
similar
approach
use
fuse
sequenc
noroviru
capsid
protein
selfassembl
vlp
interestingli
chimer
vlp
induc
respons
iav
noroviru
contain
vlp
also
obtain
coexpress
full
length
protein
iav
protein
altern
vlp
sever
group
describ
multimer
strategi
increas
immunogen
vlp
vaccin
candid
chikungunya
viru
chikv
famili
togavirida
genu
alphaviru
obtain
express
viru
structur
protein
human
cell
line
intramuscular
inocul
induc
neutral
antibodi
complet
protect
experiment
infect
nonhuman
primat
model
recombin
virus
use
sever
decad
vector
protein
express
vaccin
list
viru
famili
explor
vector
vaccin
broad
describ
detail
topic
review
recent
elsewher
virus
use
vaccin
vector
manipul
enhanc
safeti
immunogen
elimin
virul
factor
chang
tropism
replac
box
potenti
challeng
develop
vaccin
emerg
viru
incomplet
inform
knowledg
emerg
pathogen
limit
sever
reason
recent
discov
viru
outbreak
uncommon
report
natur
outbreak
import
immunolog
paramet
us
correl
protect
antigen
variabl
immunodomin
antigen
unknown
addit
highli
variabl
virus
particular
strain
caus
next
outbreak
pandem
might
unpredict
virul
biosafeti
requir
emerg
virus
high
mortal
rate
treatment
prophylaxi
avail
must
manipul
maximum
biosafeti
condit
type
virus
use
life
attenu
strain
inactiv
vaccin
requir
growth
larg
amount
viru
accept
option
similar
concern
appli
veterinari
vaccin
highli
contagi
virus
use
diseasefre
countri
lack
appropri
anim
model
vaccin
candid
need
preclin
test
anim
model
safeti
immunogen
efficaci
protect
ideal
anim
model
wellknown
immun
system
similar
suscept
immun
respons
pathogen
natur
host
import
consider
prize
size
possibl
use
larg
number
ethic
consider
possibl
differenti
infect
vaccin
anim
diva
marker
vaccin
highli
desir
veterinari
vaccin
pathogen
subject
trade
restrict
time
requir
develop
valid
massproduc
deliv
new
vaccin
ideal
short
possibl
could
facilit
use
wellknown
vaccin
platform
alreadi
test
valid
similar
pathogen
vaccin
use
control
ongo
outbreak
stockpil
advanc
produc
rapidli
induc
protect
singl
administr
short
time
inocul
envelop
protein
increas
code
capac
elimin
nonessenti
gene
one
gener
advantag
viral
vector
vaccin
antigen
express
context
actual
viral
infect
activ
innat
immun
respons
requir
full
develop
adapt
humor
cellmedi
immun
possibl
disadvantag
competit
immunodomin
antigen
vector
loss
efficaci
presenc
preexist
immun
vector
case
safeti
issu
deriv
pathogenesi
vector
also
requir
consid
interest
vaccin
emerg
virus
mani
characterist
virusvector
vaccin
includ
type
intens
immun
respons
safeti
consider
manufactur
techniqu
determin
mainli
vector
pathogen
therefor
develop
test
vaccin
newli
discov
viru
significantli
shorten
use
viral
vector
platform
extens
record
safeti
efficaci
addit
viru
famili
histor
use
vector
poxvirus
adenovirus
attract
new
vector
candid
develop
newcastl
diseas
viru
ndv
avian
paramyxoviru
infect
mammal
attenu
ndv
strain
use
vaccin
poultri
includ
dual
vaccin
ndv
avian
iav
mammal
ndv
vector
vaccin
present
two
major
advantag
first
preexist
immun
vector
second
viru
abl
block
innat
immun
respons
mammalian
cell
result
increas
safeti
immunogen
recent
recombin
ndv
express
rift
valley
fever
viru
rvfv
envelop
protein
gn
gc
shown
induc
complet
protect
mice
sheep
viral
vector
also
use
develop
vaccin
highli
pathogen
emerg
virus
ebola
virus
ebov
zoonot
filovirus
caus
hemorrhag
syndrom
high
mortal
rate
sever
vaccin
strategi
shown
induct
specif
immun
respons
protect
lethal
challeng
nonhuman
primat
experiment
vaccin
candid
use
postexposur
emerg
prophylaxi
research
accident
punctur
needl
contain
zair
ebov
consult
expert
sever
countri
chosen
vaccin
recombin
vesicular
stomat
viru
vsv
express
ebov
envelop
glycoprotein
gp
administ
hour
exposur
person
develop
antibodi
vector
gp
protein
ebov
protein
addit
vector
ebov
rna
detect
patient
serum
replic
defect
recombin
adenoviru
express
ebov
gp
elicit
complet
protect
singl
inocul
nonhuman
primat
shown
safeti
immunogen
human
possibl
caveat
strategi
vaccin
efficaci
might
affect
preexist
antibodi
vector
avail
revers
genet
techniqu
directli
manipul
genom
mani
virus
along
increas
knowledg
molecular
biolog
open
opportun
creat
new
gener
attenu
vaccin
strain
increas
safeti
immunogen
good
exampl
dn
rvfv
vaccin
candid
nonstructur
protein
nss
major
virul
factor
modul
host
immun
respons
requir
replic
cell
cultur
appli
revers
genet
exist
attenu
strain
sever
group
obtain
virus
lack
nss
demonstr
safeti
immunogen
mice
lamb
anoth
promis
strategi
creat
attenu
vaccin
exchang
sequenc
pathogen
genom
less
virul
close
relat
viru
exampl
strategi
flaviviru
vaccin
candid
base
backbon
attenu
yellow
fever
viru
strain
contain
gene
envelop
protein
prm
japanes
enceph
viru
chimerivaxj
current
licens
australia
west
nile
dengu
viru
cyd
complet
phase
ii
clinic
trial
pestiviru
chimera
combin
genom
classic
swine
fever
viru
bovin
viral
diarrhea
viru
addit
extens
use
produc
recombin
subunit
vaccin
bacteria
also
serv
vector
vivo
deliveri
antigen
dna
potenti
advantag
platform
low
cost
easi
scaleup
product
avail
well
character
attenu
strain
activ
innat
immun
vector
effici
deliveri
antigen
present
cell
sever
genera
explor
vaccin
vector
includ
listeria
salmonella
lactococcu
bordetella
recombin
bacteria
use
life
attenu
vaccin
inactiv
even
cytoplasmdeplet
bacteri
ghost
recombin
lactococcu
lacti
express
n
protein
sarscoronaviru
shown
induc
antibodi
mice
li
et
al
report
recombin
bordetella
pertusi
express
influenza
viru
induc
high
titer
specif
antibodi
mice
fail
elicit
protect
mice
inocul
cdna
encod
viral
antigen
lead
uptak
express
cdna
antigen
present
cell
initi
immun
respons
dna
vaccin
mani
potenti
advantag
vaccin
emerg
virus
plasmid
express
viral
antigen
produc
rapidli
even
partial
sequenc
inform
pathogen
avail
antigen
express
vivo
induc
humor
cellmedi
immun
respons
larg
quantiti
dna
produc
short
time
reduc
cost
dna
prepar
stabl
type
vaccin
desir
properti
vaccin
must
use
remot
area
furthermor
dna
vaccin
consid
safe
suitabl
diva
applic
affect
antivector
immun
main
limit
develop
dna
vaccin
intrins
low
immunogen
therefor
great
research
effort
invest
improv
immunogen
effici
deliveri
approach
gene
gun
skin
tattoo
electropor
target
immun
effector
cell
use
potent
adjuv
either
coadminist
vaccin
encod
plasmid
dna
vaccin
also
frequent
use
combin
vaccin
platform
primeboost
strategi
dna
vaccin
current
licens
immun
hors
wnv
undergon
phase
clinic
trial
human
dna
vaccin
evalu
candid
mani
emerg
virus
includ
ebov
rvfv
dengu
viru
chikv
replicon
vaccin
base
defect
rna
genom
abl
undergo
replic
express
encod
protein
produc
infecti
viral
particl
viral
rna
replic
strong
induc
innat
immun
therefor
replicon
vaccin
may
superior
immunogen
equival
dna
vaccin
replicon
vaccin
candid
gener
remov
essenti
structur
gene
genom
pathogen
us
west
nile
viru
rvfv
insert
replicon
heterolog
gene
encod
antigen
pathogen
far
heterolog
replicon
vaccin
use
alphaviru
deriv
replicon
review
replicon
vaccin
deliv
propagationdefect
replicon
particl
plasmid
contain
whole
replicon
sequenc
control
appropri
promot
emerg
infecti
diseas
present
mani
challeng
vaccin
develop
sever
novel
vaccin
strategi
develop
recent
year
specif
address
challeng
subunit
vaccin
contain
part
pathogen
antigen
elicit
protect
respons
differ
induc
infect
anim
contain
infecti
pathogen
need
high
biosafeti
measur
risk
accident
escap
product
residu
pathogenesi
revers
virul
vaccin
individu
use
welldefin
vaccin
platform
extens
record
safeti
efficaci
similar
pathogen
speedup
process
develop
valid
product
vaccin
new
emerg
potenti
emerg
virus
howev
mani
challeng
still
lay
ahead
specif
vaccin
platform
advantag
disadvantag
mainli
relat
balanc
safeti
immunogen
abil
use
multipl
time
studi
compar
multipl
platform
human
still
lack
futur
research
need
improv
safeti
immunolog
characterist
vaccin
strategi
icahn
school
medicin
mount
sinai
own
intellectu
properti
influenza
viru
vaccin
field
ag
one
inventor
